Dupilumab safe, effective in long-term pediatric use
Improvements in atopic dermatitis symptoms were seen in children taking dupilumab, with minimal adverse events.
Dupilumab (Dupixent; Sanofi and Regeneron) is safe and effective in treating atopic dermatitis (AD) in pediatric patients, according to a recent review.
Trials have proven dupilumab to be safe and effective for pediatric use, but proper analysis of real world dupilumab use has not been recorded.
To determine the long-term efficacy of dupilumab, researchers gathered medical records from March 2017 to September 2022 of pediatric patients with moderate to severe AD.
Information on patients’ demographics, body surface area (BSA), Eczema Area and Severity Index (EASI), and Investigator's Global Assessment (IGA) were collected.
Almost 90 patients were observed, and all saw a 75% improvement in EASI after at least 1 year of dupilumab use, with about 60% of patients seeing a 90% improvement.
Improvements were also seen in BSA and IGA. Patients with a positive history of atopy saw a greater improvement in BSA from weeks 12 to 24.
Adverse events were seen in about 14% of patients, with the most common being conjunctivitis and joint pain. No serious adverse events were observed.
Reference
Pagan AD, David E, Ungar B, Ghalili S, He H, Guttman-Yassky E. Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: areal-world, single-center study. J Allergy Clin Immunol Pract. 2022;10(9):2378-2385. doi: 10.1016/j.jaip.2022.06.014
